ZA919695B - Method of treating cancer by conjunctive therapy with n,n'-bis(3-(ethylamino)propyl)-1,7-heptanediamine and a cytotoxic agent - Google Patents

Method of treating cancer by conjunctive therapy with n,n'-bis(3-(ethylamino)propyl)-1,7-heptanediamine and a cytotoxic agent

Info

Publication number
ZA919695B
ZA919695B ZA919695A ZA919695A ZA919695B ZA 919695 B ZA919695 B ZA 919695B ZA 919695 A ZA919695 A ZA 919695A ZA 919695 A ZA919695 A ZA 919695A ZA 919695 B ZA919695 B ZA 919695B
Authority
ZA
South Africa
Prior art keywords
heptanediamine
ethylamino
propyl
bis
cytotoxic agent
Prior art date
Application number
ZA919695A
Other languages
English (en)
Inventor
Nellikunja J Prakash
J Prakash Nellikunja
Terry L Bowlin
L Bowlin Terry
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA919695B publication Critical patent/ZA919695B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA919695A 1990-12-13 1991-12-09 Method of treating cancer by conjunctive therapy with n,n'-bis(3-(ethylamino)propyl)-1,7-heptanediamine and a cytotoxic agent ZA919695B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62681490A 1990-12-13 1990-12-13

Publications (1)

Publication Number Publication Date
ZA919695B true ZA919695B (en) 1992-09-30

Family

ID=24511975

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA919695A ZA919695B (en) 1990-12-13 1991-12-09 Method of treating cancer by conjunctive therapy with n,n'-bis(3-(ethylamino)propyl)-1,7-heptanediamine and a cytotoxic agent

Country Status (11)

Country Link
EP (1) EP0490380B1 (de)
JP (1) JPH04275233A (de)
KR (1) KR100195423B1 (de)
AT (1) ATE163264T1 (de)
AU (1) AU648846B2 (de)
DE (1) DE69128926T2 (de)
DK (1) DK0490380T3 (de)
ES (1) ES2113870T3 (de)
GR (1) GR3026432T3 (de)
IE (1) IE914331A1 (de)
ZA (1) ZA919695B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910485A (en) * 1996-01-31 1999-06-08 Japan Science And Technology Corporation Antitumor agents comprising as the principal compounds containing silicon and nitrogen
US6274561B1 (en) 1997-01-29 2001-08-14 Japan Science & Technology Corp. Antitumor agents comprising as the principal compounds containing silicon and nitrogen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223340A (en) * 1987-02-03 1991-03-26 Merrell Dow Pharma Polyamine derivatives and pharmaceutical compositions
EP0378146B1 (de) * 1989-01-10 1995-03-29 Merrell Pharmaceuticals Inc. Polyamin-Derivate als antineoplastische Mittel
ZA903804B (en) * 1989-05-23 1991-03-27 Merrell Dow Pharma A method of potentiating cell-mediated immunity utilizing polyamine derivatives

Also Published As

Publication number Publication date
AU648846B2 (en) 1994-05-05
ATE163264T1 (de) 1998-03-15
ES2113870T3 (es) 1998-05-16
KR920011481A (ko) 1992-07-24
DE69128926D1 (de) 1998-03-26
JPH04275233A (ja) 1992-09-30
EP0490380A2 (de) 1992-06-17
DE69128926T2 (de) 1998-06-04
EP0490380B1 (de) 1998-02-18
EP0490380A3 (en) 1993-03-10
IE914331A1 (en) 1992-06-17
AU8890791A (en) 1992-06-18
DK0490380T3 (da) 1998-09-23
GR3026432T3 (en) 1998-06-30
KR100195423B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
HU0301601D0 (en) Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
HUT72661A (en) Orally administerable pharmaceutical formulations containing benzothiophene derivatives and process for their preparation
ZA918355B (en) Pharmaceutical compositions active in the therapy of neurological affections in aids patients,containing as an active principle at least one compound selected from the group consisting of s-adenosyl-l-methionine salt,5-methyl-tetrahydrofolic acid,5-formyltetrahydrofolic acid
ZA921292B (en) Treatment of lower urinary tract disorders.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
GR3035682T3 (en) Non-glycosylated fgf-4 and compositions containing the same.
IL86862A (en) Pharmaceutical compositions for reducing the level of circulating immune complexes in vivo, containing mismatched double-stranded rna
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
AU633867B2 (en) Delivery of cytotoxic agents
CA2033249A1 (en) Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures
ZA919695B (en) Method of treating cancer by conjunctive therapy with n,n'-bis(3-(ethylamino)propyl)-1,7-heptanediamine and a cytotoxic agent
ZA828639B (en) Novel triazoloquinazolinones, their preparation and pharmaceutical formulations containing these compounds
NZ229422A (en) Certain (2',5')-oligoadehylate derivatives and pharmaceutical use
EP0454429A3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
HU9202229D0 (en) Method for manufacturing new pharmaceutical preparatives containing 2-oxo-benzimidaazoline-1-carboxylic acid derivatives
JPS6429377A (en) 3-sulfonyl-3,7-diazabicyclo(3,3,1)nonane compound, manufacture, drug for influencing stomach and intermediate
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence
EP0311467A3 (en) Use of pyrroloû3,2,1-hi¨indole derivatives in the manufacture of a medicament for the treatment of diabetes
GR3019327T3 (en) An imidazobenzodiazepin for treating sleep disorders
PT1250926E (pt) Utilização de uma s-camptotecina insolúvel em água, com um anel de lactona fechado, no fabrico de um medicamento para o tratamento do cancro do cólon
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.
FR2700544B1 (fr) Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique.